메뉴 건너뛰기




Volumn 12, Issue 5, 2012, Pages 287-294

New anticoagulants for stroke prophylaxis in atrial fibrillation: Assessing the impact on medication adherence

Author keywords

apixaban; atrial fibrillation; dabigatran etexilate; rivaroxaban; stroke; transient ischaemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; EDOXABAN; GLYCOPROTEIN P 15095; RIVAROXABAN; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN;

EID: 84866325896     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11634130-000000000-00000     Document Type: Review
Times cited : (11)

References (30)
  • 1
    • 77957699729 scopus 로고    scopus 로고
    • Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (esc
    • Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429
    • (2010) Eur Heart J , vol.31 , pp. 2369-2429
    • Camm, A.J.1    Kirchhof, P.2    Lip, G.Y.3
  • 2
    • 0035832261 scopus 로고    scopus 로고
    • Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    • Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5
    • (2001) JAMA , vol.285 , pp. 2370-2375
    • Go, A.S.1    Hylek, E.M.2    Phillips, K.A.3
  • 3
    • 0029784441 scopus 로고    scopus 로고
    • Acute stroke with atrial fibrillation. The Copenhagen Stroke Study
    • Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27: 1765-9
    • (1996) Stroke , vol.27 , pp. 1765-1769
    • Jorgensen, H.S.1    Nakayama, H.2    Reith, J.3
  • 4
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation
    • Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1    Waterman, A.D.2    Shannon, W.3
  • 5
    • 76749163232 scopus 로고    scopus 로고
    • Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation
    • Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-72
    • (2010) Chest , vol.137 , pp. 263-272
    • Lip, G.Y.1    Nieuwlaat, R.2    Pisters, R.3
  • 6
    • 84856745317 scopus 로고    scopus 로고
    • Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 99th edition American College of Chest Physicians evidence-based clinical practice guidelines
    • You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 99th edition. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e531S-75S
    • (2012) Chest , vol.141 , Issue.2 SUPPL.
    • You, J.J.1    Singer, D.E.2    Howard, P.A.3
  • 7
    • 33746833635 scopus 로고    scopus 로고
    • Guidelines for the management of patients with atrial fibrillation
    • ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines Writing Committee to Revise the 2001
    • Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906
    • (2006) J Am Coll Cardiol , vol.48 , pp. 854-906
    • Fuster, V.1    Ryden, L.E.2    Cannom, D.S.3
  • 9
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92
    • (2011) N Engl J Med , vol.365 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 10
    • 0028244264 scopus 로고
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials
    • Atrial Fibrillation Investigators.
    • Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57
    • (1994) Arch Intern Med , vol.154 , pp. 1449-1457
  • 11
    • 0031006427 scopus 로고    scopus 로고
    • The efficacy of aspirin in patients with atrial fibrillation analysis of pooled data from 3 randomized trials
    • The Atrial Fibrillation Investigators
    • The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 1997; 157: 1237-40
    • (1997) Arch Intern Med , vol.157 , pp. 1237-1240
  • 12
    • 0037145826 scopus 로고    scopus 로고
    • Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis
    • van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002; 288: 2441-8
    • (2002) JAMA , vol.288 , pp. 2441-2448
    • Van Walraven, C.1    Hart, R.G.2    Singer, D.E.3
  • 13
    • 79952445042 scopus 로고    scopus 로고
    • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines
    • Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-7
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1330-1337
    • Wann, L.S.1    Curtis, A.B.2    Ellenbogen, K.A.3
  • 15
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th ed
    • Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 160S-98S
    • (2008) Chest , vol.133
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3
  • 16
    • 8844255607 scopus 로고    scopus 로고
    • Princeton (NJ): Dristol-Myers Squibb
    • Coumadin [package insert]. Princeton (NJ): Dristol-Myers Squibb; 2010
    • Coumadin [Package Insert , pp. 2010
  • 17
    • 77957932391 scopus 로고    scopus 로고
    • Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the effective anticoagulation with factor x a next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (engage af-timi 48
    • Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor x. A next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635-41
    • (2010) Am Heart J , vol.160 , pp. 635-641
    • Ruff, C.T.1    Giugliano, R.P.2    Antman, E.M.3
  • 19
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 20
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 21
    • 78049490509 scopus 로고    scopus 로고
    • Newly identified events in the RE-LY trial [letter
    • for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al., for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial [letter]. N Engl J Med 2010; 363 (19): 1875-6
    • (2010) N Engl J Med , vol.363 , Issue.19 , pp. 1875-1876
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 22
    • 80052836882 scopus 로고    scopus 로고
    • A new era for anticoagulation in atrial fibrillation
    • Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011; 365: 1052-4
    • (2011) N Engl J Med , Issue.365 , pp. 1052-1054
    • Mega, J.L.1
  • 23
    • 79952301326 scopus 로고    scopus 로고
    • Apixaban in patients with atrial fibrillation
    • Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17
    • (2011) N Engl J Med , vol.364 , pp. 806-817
    • Connolly, S.J.1    Eikelboom, J.2    Joyner, C.3
  • 24
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate: A novel, reversible, oral direct thrombin inhibitor. Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: A novel, reversible, oral direct thrombin inhibitor. Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27
    • (2010) Thromb Haemost , vol.103 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3
  • 25
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo- controlled, crossover study in healthy subjects
    • Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo- controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9
    • (2011) Circulation , Issue.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3
  • 26
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • Letter
    • Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366 (9): 864-6. Letter
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 27
  • 28
    • 69849098585 scopus 로고    scopus 로고
    • Effect of medication dosing frequency on adherence in chronic diseases
    • Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-33
    • (2009) Am J Manag Care , vol.15
    • Saini, S.D.1    Schoenfeld, P.2    Kaulback, K.3
  • 29
    • 0034871011 scopus 로고    scopus 로고
    • A systematic review of the associations between dose regimens and medication compliance
    • Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310
    • (2001) Clin Ther , vol.23 , pp. 1296-1310
    • Claxton, A.J.1    Cramer, J.2    Pierce, C.3
  • 30
    • 84860710460 scopus 로고    scopus 로고
    • Adherence and dosing frequency of common medications for cardiovascular patients
    • Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients.AmJ Manag Care 2012; 18: 139-46
    • (2012) AmJ Manag Care , Issue.18 , pp. 139-146
    • Bae, J.P.1    Dobesh, P.P.2    Klepser, D.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.